Vivani Medical (Nasdaq:VANI) today announced third-quarter earnings results that included timeline updates on its semaglutide implant. The Alameda, California-based company develops NanoPortal technology, which steadily delivers medication over extended periods of time. Vivani aims to guarantee correct patient doses while avoiding potential safety concerns around fluctuating drug release profiles. It can also deliver large hydrophilic […]
Drug-Device Combinations
What the launch of Mobi for Android means for Tandem, people with diabetes
This week, Tandem Diabetes Care (Nasdaq:TNDM) announced a major milestone for its Mobi miniature durable insulin pump system. San Diego-based Tandem revealed that it received FDA approval for the Android version of its Mobi mobile app. Clearance brings Mobi — which the company describes as the world’s smallest, durable automated insulin delivery system — to […]
Go-Pen wins CE mark for user-fillable insulin pen
Go-Pen announced today on social media that it received CE mark approval for its user-fillable insulin pen. The Denmark-based company said on LinkedIn that, with CE mark now in hand, adding to FDA clearance achieved in May, it now has the foundation needed to bring its insulin pen technology to the U.S. and European market. […]
Tandem wins FDA nod to pair Mobi pump with Android smartphones
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received FDA approval for the Android version of its Mobi mobile app. Clearance brings Mobi — which the company describes as the world’s smallest, durable automated insulin delivery system — to more users. The pump, which pairs with Tandem’s Control-IQ+ algorithm, previously worked with iOS software. Tandem’s […]
The top CGM stories of 2025
Millions of people worldwide are looking for ways to manage their diabetes. That’s where the continuous glucose monitor (CGM) comes in. The CGM market is expected to experience substantial, double-digit percentage growth over the next five years, reaching nearly $29 billion by 2030. Market leaders Abbott and Dexcom continue to establish their hold on the […]
Billie Jean King supports Medtronic Diabetes awareness initiative
The annual Medtronic (NYSE:MDT) diabetes awareness initiative this year has the backing of sporting legend Billie Jean King. King, a former world No. 1 tennis player and pioneer in women’s sports, is participating in the company’s Blue Balloon Challenge this year. Introduced in 2021, the movement encourages people with diabetes to help drive awareness and […]
Tandem stock rises after hours on Q3 beats, record sales
Tandem Diabetes Care (Nasdaq:TNDM) shares got a boost after hours today on third-quarter results that came in ahead of the consensus forecast. Shares of TNDM rose nearly 20% to $15.89 apiece in post-market trading today. The San Diego-based automated insulin delivery technology developer reported losses of $21.2 million. That equals 31¢ per share on sales […]
Insulet leadership talks patch pump competition, expanding type 2 diabetes market
As Insulet (Nasdaq:PODD) continues to grow in its leadership position within the insulin patch pump market, other entries could be on the way. The Acton, Massachusetts–based company’s Omnipod platform has long been the leader in the patch pump space, with the latest-generation Omnipod 5 delivering nearly $700 million in revenue in the company’s recently announced […]
Insulet increases guidance again on Q3 beats, 30% sales uptick
Insulet (Nasdaq:PODD) shares rose slightly before hours today on third-quarter results that landed well ahead of the consensus forecast. Shares of PODD ticked up 2.4% to $322 apiece in pre-market trading today. The Acton, Massachusetts-based automated insulin delivery technology developer reported profits of $87.6 million. That equals $1.24 per share on sales of $706.3 million […]
Senseonics posts Q3 sales beat, expects CE mark for Eversense 365 this year
Senseonics (NYSE:SENS) shares ticked up after hours today on third-quarter results that beat the consensus sales forecast. Shares of SENS rose 2.1% to $6.87 apiece in post-market trading today. The Germantown, Maryland-based long-term implantable continuous glucose monitor (CGM) maker reported losses of $19.5 million. That equals 43¢ per share on sales of $8.1 million for […]
